Bahl & Gaynor Inc. Increases Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Bahl & Gaynor Inc. increased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 4.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 125,599 shares of the medical instruments supplier’s stock after buying an additional 5,207 shares during the quarter. Bahl & Gaynor Inc. owned about 0.56% of LeMaitre Vascular worth $7,129,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the business. BluePath Capital Management LLC purchased a new stake in LeMaitre Vascular in the third quarter valued at approximately $31,000. DekaBank Deutsche Girozentrale purchased a new stake in LeMaitre Vascular during the 3rd quarter worth $38,000. Campbell & CO Investment Adviser LLC increased its holdings in LeMaitre Vascular by 78.8% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 5,329 shares of the medical instruments supplier’s stock valued at $290,000 after purchasing an additional 2,349 shares in the last quarter. Panagora Asset Management Inc. purchased a new stake in shares of LeMaitre Vascular in the third quarter worth about $315,000. Finally, Quantbot Technologies LP grew its stake in shares of LeMaitre Vascular by 709.6% in the third quarter. Quantbot Technologies LP now owns 7,578 shares of the medical instruments supplier’s stock valued at $413,000 after buying an additional 6,642 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Trading Up 3.9 %

LeMaitre Vascular stock traded up $2.47 during mid-day trading on Friday, reaching $65.46. The company’s stock had a trading volume of 117,291 shares, compared to its average volume of 111,857. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of 48.85, a PEG ratio of 2.76 and a beta of 0.87. LeMaitre Vascular, Inc. has a twelve month low of $44.27 and a twelve month high of $74.64. The business has a 50 day moving average price of $65.35 and a 200-day moving average price of $58.10.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of $0.36 by $0.02. LeMaitre Vascular had a net margin of 15.56% and a return on equity of 10.57%. The business had revenue of $48.90 million during the quarter, compared to the consensus estimate of $49.01 million. During the same quarter in the prior year, the firm earned $0.25 EPS. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. On average, equities analysts expect that LeMaitre Vascular, Inc. will post 1.66 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Thursday, March 14th were given a dividend of $0.16 per share. The ex-dividend date of this dividend was Wednesday, March 13th. This represents a $0.64 dividend on an annualized basis and a yield of 0.98%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.14. LeMaitre Vascular’s payout ratio is currently 47.76%.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 36,600 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $68.03, for a total value of $2,489,898.00. Following the completion of the transaction, the chief executive officer now owns 2,187,526 shares in the company, valued at approximately $148,817,393.78. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CEO George W. Lemaitre sold 36,600 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $68.03, for a total value of $2,489,898.00. Following the completion of the transaction, the chief executive officer now owns 2,187,526 shares in the company, valued at approximately $148,817,393.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Joseph P. Pellegrino, Jr. sold 36,967 shares of the business’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $69.76, for a total transaction of $2,578,817.92. Following the sale, the chief financial officer now owns 6,452 shares in the company, valued at $450,091.52. The disclosure for this sale can be found here. Insiders sold a total of 114,036 shares of company stock worth $7,873,749 in the last three months. 10.79% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

LMAT has been the subject of several recent research reports. Stifel Nicolaus raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and increased their price objective for the company from $59.00 to $75.00 in a research report on Friday. KeyCorp initiated coverage on shares of LeMaitre Vascular in a report on Tuesday, February 6th. They set a “sector weight” rating for the company. Barrington Research boosted their price objective on shares of LeMaitre Vascular from $66.00 to $69.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th. Finally, StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, April 16th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, LeMaitre Vascular currently has an average rating of “Moderate Buy” and a consensus target price of $69.33.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.